News
-
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets -
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics reports promising preliminary results of RLF-TD011 clinical trial for epidermolysis bullosa, showing reduced Staphylococcus aureus and improved microbiome diversity -
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Relief Therapeutics reports positive results from RLF-OD032 proof-of-concept clinical study for Phenylketonuria, showing bioequivalence with KUVAN(R) in managing PKU. RLF-OD032 aims to offer a patient-friendly, portable solution for PKU treatment -